期刊
INVESTIGATIONAL NEW DRUGS
卷 40, 期 4, 页码 700-708出版社
SPRINGER
DOI: 10.1007/s10637-022-01229-3
关键词
beta-Thujaplicin; Head and neck squamous cell carcinoma; cancer; HNSCC; Radiosensitization
This study found that beta-Thujaplicin can enhance the sensitivity of HNSCC cell lines to radiotherapy and inhibit cell clonogenicity and migration.
Background Resistance to radiotherapy is a common cause of treatment failure in advanced head and neck squamous cell carcinoma (HNSCC). beta-Thujaplicin, a natural tropolone derivative, acts as an anti-cancer agent and has recently been shown to radiosensitize non-HNSCC cancer cells. However, no data is currently available on its radiosensitizing potential in HNSCC. Methods To investigate the effect of beta-Thujaplicin and irradiation in HNSCC cell lines CAL27 and FADU, we performed a cell viability assay, colony forming assay, flow cytometry for cell cycle analysis and a wound healing assay. Drug-irradiation interaction was analyzed using a zero-interaction potency model. Results Treatment with beta-Thujaplicin led to a dose-dependent decrease in cell viability and enhanced the effect of irradiation. Clonogenic survival was inhibited with synergistic drug-irradiation interaction. beta-Thujaplicin further led to S-phase arrest and increased the sub-G1 population. Moreover, combined beta-Thujaplicin and irradiation treatment had a higher anti-migratory effect compared to irradiation alone. Conclusions beta-Thujaplicin acts as a radiosensitizer in HNSCC cell lines. Further evaluation of its use in HNSCC therapy is warranted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据